Pharmaceutical Executive, October 2017 Issue (PDF)

In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory nodule count.

Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.

Company executives provide updates on cancer treatment pelareorep and other elements of the company’s pipeline.

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

The Project Farma president discusses various ways the tariffs could impact the industry and how businesses can prepare or react.

In an era where business-critical information is exchanged instantly, unsecured communication channels are a significant risk.